Stereotactic body radiation therapy to the prostate bed: results of a phase I dose escalation trial.
The primary objectives of this study were to evaluate toxicity of escalating doses of prostate bed SBRT and provide dose recommendations for phase II study. Patients with organ-confined, node-negative prostate cancer who had biochemical failure (Prostate-specific antigen [PSA] less than 2.0) following prostatectomy were eligible for this phase I dose escalation trial. Doses delivered were 35 Gy, 40 Gy, and 45 Gy in 5 fractions, given every other day. Dose-limiting toxicity (DLT) was defined as CTCAE (version 4) grade 3 or higher gastrointestinal (GI) or genitourinary (GU) toxicity within 90 days of treatment. Maximum tolerated dose (MTD) was the highest dose to be tested where <2 of the patients experienced DLT. Patients completed quality of life questionnaires at regular time intervals. Twenty-six patients completed treatment between October 2013 and December 2017. Three patients received 35 Gy, 8 patients received 40 Gy, and 15 patients received 45 Gy. The median follow-up was 60 months for 35 Gy, 48 months for 40 Gy, and 33 months for 45 Gy. No acute DLT events were observed. Late Grade >=2 and >=3 GI toxicity occurred in 11% and 0%, respectively, and late grade >=2 and >=3 GU toxicity occurred in 38% and 15%, respectively. No difference was observed in late GU toxicity between 40 Gy and 45 Gy. Sexual function scores were significantly lower in the patients receiving ADT (p<0.01). In all patients, the crude rate of PSA control (<0.2 ng/mL) was 11/26 (42%). Dose escalation to 45 Gy did not result in acute DLT events, had similar rates of late grade 3 toxicity, and did not demonstrate higher rates of PSA control, compared to 40 Gy. While allowing for higher plan heterogeneity, the recommended dose for phase II study will be 40 Gy in 5 fractions.